Upon tumor challenge of MS-OVA vaccinated mice, the proliferation of OVA-specific CD8+ T cells does occur, however higher frequencies are reached in mice that eventually succumb to tumor burden (Figure 5). This evidence concerns the gene CD8A and neoplasm.